{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:05:29Z","timestamp":1768806329518,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"institutional grants Progress","award":["8514001"],"award-info":[{"award-number":["8514001"]}]},{"name":"institutional grants Progress","award":["Q40\/01"],"award-info":[{"award-number":["Q40\/01"]}]},{"name":"InoMed project","award":["OPVaVCZ.02.1.01\/0.0\/0.0\/18_069\/0010046"],"award-info":[{"award-number":["OPVaVCZ.02.1.01\/0.0\/0.0\/18_069\/0010046"]}]},{"name":"Czech Scientific Agency GACR","award":["17-06841S"],"award-info":[{"award-number":["17-06841S"]}]},{"name":"GAUK","award":["170\/50\/85006"],"award-info":[{"award-number":["170\/50\/85006"]}]},{"name":"GAUK","award":["SVV 260 549"],"award-info":[{"award-number":["SVV 260 549"]}]},{"name":"Technology Agency of the Czech Republic: Czech National Centres of Competence, project\u2019 \u2019PerMed \u201cPersonalized Medicine \u2013 Diagnostics and Therapy","award":["TN01000013"],"award-info":[{"award-number":["TN01000013"]}]},{"name":"Academy of Sciences of the Czech Republic (AS CR) \u2013 grant","award":["RVO 61388963"],"award-info":[{"award-number":["RVO 61388963"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jsbmb.2020.105702","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T11:45:33Z","timestamp":1591271133000},"page":"105702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["3\u03b2-Isoobeticholic acid efficiently activates the farnesoid X receptor (FXR) due to its epimerization to 3\u03b1-epimer by hepatic metabolism"],"prefix":"10.1016","volume":"202","author":[{"given":"Alzbeta","family":"Stefela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Kaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Drastik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Holas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos","family":"Hroch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Smutny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Skoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriama","family":"Hutn\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit V.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"Micuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kudova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Pavek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2020.105702_bib0005","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0010","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.1070477","article-title":"Vitamin D receptor as an intestinal bile acid sensor","volume":"296","author":"Makishima","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0015","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1073\/pnas.051551698","article-title":"The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity","volume":"98","author":"Staudinger","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2018.12.018","article-title":"Developments in bile salt based therapies: a critical overview","volume":"161","author":"Donkers","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2019_237","article-title":"Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists, and antagonists","volume":"256","author":"De Marino","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0030","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.molmed.2015.09.001","article-title":"Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders","volume":"21","author":"Fiorucci","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0035","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00018-014-1805-y","article-title":"Nuclear bile acid signaling through the farnesoid X receptor","volume":"72","author":"Mazuy","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0040","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1159\/000445268","article-title":"Farnesoid X receptor agonists and other bile acid signaling strategies for treatment of liver disease","volume":"34","author":"Halilbasic","year":"2016","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0045","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and challenges of selective farnesoid X receptor modulation","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOG.0000000000000525","article-title":"Obeticholic acid in primary biliary cholangitis: where we stand","volume":"35","author":"Manne","year":"2019","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0065","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/liv.13974","article-title":"Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis","volume":"39","author":"Chalasani","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0070","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic acid: an update of its pharmacological activities in liver disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0080","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0085","doi-asserted-by":"crossref","first-page":"19008","DOI":"10.1038\/srep19008","article-title":"Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists","volume":"6","author":"Sepe","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0090","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","article-title":"Farnesoid X receptor modulators 2014-present: a patent review","volume":"28","author":"Sepe","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0095","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4155\/fmc.15.54","article-title":"Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application","volume":"7","author":"Sepe","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0100","unstructured":"patent_WO2015\/181275A1, BAR Pharmaceutical S.R.L."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0105","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1194\/jlr.R900007-JLR200","article-title":"Bile acids as regulatory molecules","volume":"50","author":"Hylemon","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0110","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/1873-3468.13064","article-title":"Metabolism of hydrogen gases and bile acids in the gut microbiome","volume":"592","author":"Hylemon","year":"2018","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0115","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/cts.12468","article-title":"Metabolic profile of obeticholic acid and endogenous bile acids in rats with decompensated liver cirrhosis","volume":"10","author":"Roda","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0304-4165(01)00096-4","article-title":"Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats","volume":"1526","author":"Purucker","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0125","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a human hepatoma cell line by hepatitis B virus","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0130","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/bph.13472","article-title":"The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for (\"squelching\") SRC-1 coactivator","volume":"173","author":"Hyrsova","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.toxlet.2016.11.013","article-title":"Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor","volume":"265","author":"Carazo","year":"2017","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.toxlet.2010.11.008","article-title":"Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia?","volume":"200","author":"Vrzal","year":"2011","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tox.2012.10.018","article-title":"Cholestatic effect of epigallocatechin gallate in rats is mediated via decreased expression of Mrp2","volume":"303","author":"Hirsova","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0150","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1111\/j.1538-7836.2010.04036.x","article-title":"Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes","volume":"8","author":"Rulcova","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0155","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbalip.2017.09.003","article-title":"Iron depletion induces hepatic secretion of biliary lipids and glutathione in rats","volume":"1862","author":"Prasnicka","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0160","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/jm401873d","article-title":"Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors","volume":"57","author":"D\u2019Amore","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0165","article-title":"Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism","volume":"5","author":"Di Leva","year":"2015","journal-title":"Sci. Rep.-UK"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0170","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Software news and update autoDock vina: improving the speed and accuracy of docking with a New scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0175","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1021\/ac503816u","article-title":"Metabolic profiling of bile acids in human and mouse blood by LC\u2013MS\/MS in combination with phospholipid-depletion solid-phase extraction","volume":"87","author":"Han","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0180","doi-asserted-by":"crossref","first-page":"20903","DOI":"10.1074\/jbc.271.34.20903","article-title":"Purification of a 3beta-hydroxy-delta5-C27-steroid dehydrogenase from pig liver microsomes active in major and alternative pathways of bile acid biosynthesis","volume":"271","author":"Furster","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0185","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2016.01.016","article-title":"Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid","volume":"64","author":"Ijssennagger","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0190","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.dld.2013.10.021","article-title":"The bile acid TGR5 membrane receptor: from basic research to clinical application","volume":"46","author":"Duboc","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0195","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/jm401873d","article-title":"Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors","volume":"57","author":"D\u2019Amore","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0200","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1021\/ml400247k","article-title":"Probing the binding site of bile acids in TGR5","volume":"4","author":"Macchiarulo","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejmech.2015.09.024","article-title":"Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists","volume":"104","author":"Gertzen","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0210","series-title":"OCALIVA, (Package Insert)","year":"2018"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0215","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0220","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0225","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0230","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0235","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1042\/BJ20060537","article-title":"Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation","volume":"398","author":"Vassileva","year":"2006","journal-title":"Biochem. J."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0240","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1210\/me.2010-0460","article-title":"The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling","volume":"25","author":"Li","year":"2011","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0245","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fphar.2017.00162","article-title":"Targeting bile acid receptors: discovery of a potent and selective farnesoid X receptor agonist as a new lead in the pharmacological approach to liver diseases","volume":"8","author":"Festa","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0250","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1021\/jm501273r","article-title":"Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands","volume":"57","author":"Festa","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0255","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jm049904b","article-title":"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid","volume":"47","author":"Pellicciari","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0260","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0265","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acsmedchemlett.7b00318","article-title":"Synthesis and biological evaluation of a series of bile acid derivatives as FXR agonists for treatment of NASH","volume":"8","author":"Xiao","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1124\/mol.110.064501","article-title":"Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist","volume":"78","author":"Rizzo","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0275","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1021\/jm901390p","article-title":"Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity","volume":"52","author":"Pellicciari","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0280","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24061043","article-title":"Introduction of nonacidic Side chains on 6-ethylcholane scaffolds in the identification of potent bile acid receptor agonists with improved pharmacokinetic properties","volume":"24","author":"Finamore","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0285","doi-asserted-by":"crossref","first-page":"9201","DOI":"10.1021\/acs.jmedchem.6b01126","article-title":"Discovery of 3alpha,7alpha,11beta-trihydroxy-6alpha-ethyl-5beta-cholan-24-oic acid (TC-100), a novel bile acid as potent and highly selective FXR agonist for enterohepatic disorders","volume":"59","author":"Pellicciari","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0290","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1194\/jlr.M300215-JLR200","article-title":"Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation","volume":"45","author":"Fujino","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0295","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1172\/JCI10902","article-title":"The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis","volume":"106","author":"Schwarz","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0300","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1038\/s41467-019-10853-2","article-title":"Molecular tuning of farnesoid X receptor partial agonism","volume":"10","author":"Merk","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0305","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/164_2019_234","article-title":"Structural insight into the binding mode of FXR and GPBAR1 modulators","volume":"256","author":"Di Leva","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jsbmb.2020.105702_bib0310","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1097-2765(03)00112-6","article-title":"Structural basis for bile acid binding and activation of the nuclear receptor FXR","volume":"11","author":"Mi","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jsbmb.2020.105702_bib0315","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.steroids.2015.11.003","article-title":"Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity","volume":"105","author":"Sepe","year":"2016","journal-title":"Steroids"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076020302272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076020302272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:04:46Z","timestamp":1760745886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076020302272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":63,"alternative-id":["S0960076020302272"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105702","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3\u03b2-Isoobeticholic acid efficiently activates the farnesoid X receptor (FXR) due to its epimerization to 3\u03b1-epimer by hepatic metabolism","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105702"}}